Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven’s lead investigational drug from its Molecular Degrader of Extracellular Proteins (MoDE™) platform BHV-1300 demonstrates dose-dependent and rapid IgG reductions within hours of administration No SAEs,…